Literature DB >> 29997981

miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC).

Yichao Han1, Hecheng Li1.   

Abstract

Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer death globally, of which 85% is non-small cell lung cancer (NSCLC). Early detection of NSCLC is essential to identify potential individuals for radical cure. Although low-dose computed tomography (LDCT) is recommended as standard screening with a mortality reduction of 20%, it displays a high false positive rate that poses an issue of overdiagnosis. MicroRNAs (miRNAs) are a group of small non-coding RNAs acting as important regulators in post-transcriptional gene expression and have been studied for their extensive role as novel biomarkers in NSCLC. Herein, we discuss the miRNA biology, its role in cancer, the potential of biomarkers both in cancer and NSCLC, and promising current publications of diagnostic biomarkers for early detection in NSCLC, especially studies in order to complement LDCT screening.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); biomarkers; early detection; microRNAs (miRNAs)

Year:  2018        PMID: 29997981      PMCID: PMC6006134          DOI: 10.21037/jtd.2018.05.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  100 in total

Review 1.  Circulating cell-free microRNAs as clinical cancer biomarkers.

Authors:  Virginie Armand-Labit; Anne Pradines
Journal:  Biomol Concepts       Date:  2017-05-24

2.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

3.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

4.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Authors:  Elena Gallardo; Alfons Navarro; Nuria Viñolas; Ramon M Marrades; Tania Diaz; Bernat Gel; Angels Quera; Eva Bandres; Jesus Garcia-Foncillas; Jose Ramirez; Mariano Monzo
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

5.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

8.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

9.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

Review 10.  Circulating miRNAs in cancer: from detection to therapy.

Authors:  Wen-Tao Wang; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

View more
  10 in total

Review 1.  Clinical applications of liquid biopsies for early lung cancer detection.

Authors:  Hao Zheng; Xin Wu; Jie Yin; Shuang Wang; Zhi Li; Changxuan You
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

2.  Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.

Authors:  Radu Pirlog; Paul Chiroi; Ioana Rusu; Ancuta Maria Jurj; Liviuta Budisan; Cecilia Pop-Bica; Cornelia Braicu; Doinita Crisan; Jean-Christophe Sabourin; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

3.  microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1.

Authors:  Wei Zhou; Ruichao Li
Journal:  Onco Targets Ther       Date:  2019-05-17       Impact factor: 4.147

4.  CircRNA CDR1as knockdown inhibits progression of non-small-cell lung cancer by regulating miR-219a-5p/SOX5 axis.

Authors:  Yaming Li; Jinzhao Zhang; Shuang Pan; Jing Zhou; Xin Diao; Song Liu
Journal:  Thorac Cancer       Date:  2020-01-09       Impact factor: 3.500

5.  Integrated Network Analysis Reveals FOXM1 and MYBL2 as Key Regulators of Cell Proliferation in Non-small Cell Lung Cancer.

Authors:  Firoz Ahmed
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 6.  Liquid biopsies to distinguish malignant from benign pulmonary nodules.

Authors:  Rui Tao; Wei Cao; Feng Zhu; Jinfu Nie; Hongzhi Wang; Lixiang Wang; Pengcheng Liu; Hailong Chen; Bo Hong; Dahai Zhao
Journal:  Thorac Cancer       Date:  2021-05-07       Impact factor: 3.500

7.  circ_0002346 Suppresses Non-Small-Cell Lung Cancer Progression Depending on the Regulation of the miR-582-3p/STXBP6 Axis.

Authors:  Weijie Wang; Yi Lin; Guanghui Zhang; Guofu Shi; Yongsheng Jiang; Wentao Hu; Wei Zuo
Journal:  Int J Genomics       Date:  2021-10-20       Impact factor: 2.326

Review 8.  [Role and Significance of Bioactive Substances in Sputum
 in the Diagnosis of Lung Cancer].

Authors:  Yuming Jin; Zixuan Chen; Quan Chen; Leihao Sha; Cheng Shen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-12-20

Review 9.  MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?

Authors:  Daniel Humberto Pozza; Ramon Andrade De Mello; Raphael L C Araujo; Vamsidhar Velcheti
Journal:  Curr Genomics       Date:  2020-08       Impact factor: 2.236

10.  Molecular Beacon for Detection miRNA-21 as a Biomarker of Lung Cancer.

Authors:  Daniela Alexandre; Bernardo Teixeira; André Rico; Salete Valente; Ana Craveiro; Pedro V Baptista; Carla Cruz
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.